McCormick is also an international story, said Wilson, with his company investing in emerging markets around the world to build its business. He said nearly one-third of all new products are also a result a new technology with improvements in both flavors and efficiencies.
When asked about the company's product strategy, Wilson said McCormick offers a broad mix of items from private label to branded items to gourmet products for every type of customer.
Cramer said McCormick is a great growth story and he continues to recommend owning it.
Merck on the Mend
For the next installment of his Big Pharma series, Cramer highlighted
(MRK - Get Report)
, an Action Alerts PLUS holding that has lagged the industry and is up only 6% so far this year.
Cramer said that while Merck trades at just 12 times earnings, compared to an industry average of 14 times earnings, the company is actually in excellent shape with a broad pipeline of new drugs and a 3.8% yield. While many Big Pharma names have suffered the wrath of the "patent cliff," Merck now has the least exposure to generic competition.
Among the many positives in Merck's favor is the company's 2009 acquisition of Schering-Plough and its growing animal health business, which racked up $3.4 billion in sales last year. Merck also has a strong diabetes franchise as well as a vaccine business worth $5.8 billion in sales.
Merck's strong pipeline of new drugs is also a plus, said Cramer. The company should have no fewer than five drugs ready for approval this year alone. He said that while Merck may not have many home runs in its portfolio, it's a solid base hitter that can deliver over and over again.
Cramer concluded by saying that Merck should easily be a $60 stock.
In the Lightning Round, Cramer was bullish on
Sirius XM Radio
Enbridge Energy Partners
Cramer was bearish on
Off the Charts
In the "Off The Charts" segment, Cramer went head to head with colleague Bob Lang over the outlook for the online travel sector, pitting the technicals against the fundamentals to see which travel stocks make the grade.
(PCLN - Get Report)
remains the "best of breed" player, and Lang's research agreed. Lang noted that after a giant move since January, shares have been consolidating but still holding above their uptrend line. The MACD momentum indicator is signaling a powerful buy signal, meaning this stock is poised for another move higher.
Lang saw similar patterns in
(EXPE - Get Report)
, noting this stock has a solid floor of support at $60. The MACD is also signaling a buy signal and the Williams oscillator confirms strength in Expedia as well.
, a stock that has tripled since its November lows on strong volume. The stock stalled in mid-March, but also seems poised to follow the group higher. Cramer said he's not a fan of Orbitz and would prefer Priceline or Expedia over this distant-third player.
(TRIP - Get Report)
, the only company of the group that relies on advertising rather than booking fees. Cramer said while this stock has support at its 50-day moving average, he's not a fan given that advertising rates are on the decline.
No Huddle Offense
In his "No Huddle Offense" segment, Cramer opined on the continued collapse of
. He said investors need to steer clear of Penney because the retailer could indeed go away entirely, and owning it is simply not worth the risk.
That's good news for
, said Cramer, as that chain will likely pick up most of Penney's business. He also likes
, an Action Alerts PLUS name.
seems to have lost its way and will not be a big gainer of customers fleeing Penney.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC
-- Written by Scott Rutt in Washington, D.C.
To email Scott about this article, click here:
Follow Scott on Twitter
or get updates on Facebook,